factual
Combined CTLA-4 and PD-1 blockade gives 55% 10-year survival
Combining the anti-CTLA-4 checkpoint blockade with anti-PD-1 (a different checkpoint discovered by Tasuku Honjo, Arlene Sharp, and Gordon Freeman) produced, in a gold-standard randomized trial of over a thousand patients across 10 countries with 10-year follow-up, 55% of metastatic melanoma patients still alive—transforming an almost uniformly fatal disease into one where more than half are cured.
factualpending
Speaker
James P. AllisonEvidence Quote
“10 years follow up, 55% of the patients were still alive.”
Created: 6/13/2026, 12:24:01 AM
Your notes
Loading notes...